Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Sorrento Therapeutics Fell 20.7% in September

By Maxx Chatsko - Oct 11, 2018 at 5:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A recently announced debt financing won't dilute shareholders, but it still has Wall Street worried.

What happened

Shares of Sorrento Therapeutics (SRNE -1.59%) dropped nearly 21% last month, according to data provided by S&P Global Market Intelligence. The stock's September slide was triggered by an announcement that the company's majority-owned subsidiary Scilex entered into a debt-financing deal that would provide $140 million.

While that cash inflow will be needed to hit the ground running when marketing the duo's first commercial product, there's a catch: The debt will be repaid using royalties on product sales. That will limit the financial benefit captured by Sorrento Therapeutics as it transitions to commercial operations, which had investors and analysts second-guessing the company's $600 million valuation at the time of the announcement.

A stock chart showing losses on a touchscreen.

Image source: Getty Images.

So what

Sorrento Therapeutics stock has gained about 37% since the beginning of the year, thanks in large part to the excitement surrounding the launch of its first product ZTlido, which is a patch approved to treat post-shingles pain. Due to ZTlido's ability to be worn for 12 hours and even during exercise, the company has high hopes for the product to capture market share from existing lidocaine-administering patches. But it's not exactly a slam-dunk.

The excitement for approval was somewhat tempered by concerns that the company's marketing inexperience could delay a sales ramp up or limit market penetration, in addition to the name recognition of the market's leading patch, Lidoderm (and a healthy amount of generic patches). Now, on top of that fairly standard uncertainty for a newly commercial company, analysts are concerned that the new debt financing will keep shareholders from fully benefiting from a successful launch.

Now what

Worries over the details of the recent debt financing, in which the company will need to repay the loan using proceeds from the sale of its first commercial product, should not be overlooked. That's especially true considering Sorrento Therapeutics posted an operating loss of nearly $61 million in the first half of 2018. If ZTlido stumbles out of the gate or doesn't sell well enough to meet debt-payment obligations, then shareholders could be significantly harmed.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.54 (-1.59%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.